Up-Down-Up-Down: Canadian Cannabis Volatility Continued Last Week

Image source

The volatility continues! The 5 constituents in munKNEE's Canadian Cannabis LPs Index were up 1.8% last week after having gone down the previous week, up 12,5% the week before that and down 3.9% the week before that. 

Below are the performances of the constituents in the Index last week, in descending order, and for the previous week along with each stock's forward-price-to-sales ratio (PSR), and enterprise value-to-earnings before interest, taxes, depreciation and amortization (EV/EBITDA) ratio to provide a comparative valuation of each, where applicable, plus the latest news on each company. A definition of each ratio is at the end of the article.

Canadian Cannabis LPs Index

  1. Cronos Group (CRON): down 4.9% last week; up 10.8% the previous week
  2. Organigram Holdings (OGI): up 2.4% last weekup 6.0% the previous week
  3. Aurora Cannabis (ACB): down 2.1% last week; down 4.1% the previous week
  4. Tilray Brands (TLRY): up 9.6% last week; down 12.6% the previous week
  5. Canopy Growth (CGC): up 5.8% last week; down 17.5% the previous week

LP Stock Performance Summary

Index Average: up 1.8% last week, down 1.7% the previous week and now down 47.2% YTD.


Valuation Metrics 

To evaluate these companies, investors often look at these key ratios, among others:

  • The price-to-sales ratio (PSR) indicates the price paid for a share relative to the revenue that share generates, helping assess if a stock is valued appropriately. The mean forward PSR for the EDA Software Sector is 2.5 and is considered excellent when the value falls below two (2). The mean forward PSR for the Health Care/Pharmaceuticals sector is 3.6.
  • The Enterprise Value-to-Earnings Before Interest, Taxes, Depreciation, and Amortization ratio (EV/EBITDA) ratio considers a company's total value, including debt and equity, relative to its earnings before interest, taxes, depreciation, and amortization, giving investors insight into profitability across companies. A high means the company is overvalued, while a low ratio indicates it’s undervalued. The mean forward EV/EBITDA ratio for the Health Care/Pharmaceuticals sector is 12.8.

More By This Author:

Quantum Computing Hardware Developers Index Up This Week
Top 15 AI Stocks Were Up 5% This Week; Two May Still Be Undervalued
Cresco Labs Q3 Financial Metrics Mixed

Disclosure: None

Visit  munKNEE.com and register to receive our free Market Intelligence Report newsletter (sample  more

How did you like this article? Let us know so we can better customize your reading experience.

Comments

Leave a comment to automatically be entered into our contest to win a free Echo Show.
Or Sign in with